Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab (R-CHOP) Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell (DLBCL) NHL: Southwest Oncology Group Study S0515

被引：0
|
作者：
Stopeck, Alison T. [1 ]
Unger, Joseph M. [2 ]
Rimsza, Lisa M. [3 ]
Farnsworth, Brent [3 ]
LeBlanc, Michael [2 ]
Iannone, Maria [1 ]
Fisher, Richard I. [4 ]
Miller, Thomas P. [1 ]
机构：
[1] Arizona Canc Ctr, Tucson, AZ USA
[2] SW Oncol Grp, Seattle, WA USA
[3] Univ Arizona, Tucson, AZ USA
[4] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：260 / 261
页数：2
相关论文
共 50 条
  • [31] Phase 3 trial of subcutaneous epcoritamab plus R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2.
    Sehn, Laurie Helen
    Chamuleau, Martine
    Lenz, Georg
    Clausen, Michael
    Haioun, Corinne
    Izutsu, Koji
    Davies, Andrew John John
    Zhu, Jun
    Oki, Toshiko
    Szafer-Glusman, Edith
    Conlon, Rebekah
    Chiou, Hueiyu
    Ipe, David
    Elliott, Brian
    Wu, Jun
    Salles, Gilles A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial
    Gleeson, Mary
    Hawkes, Eliza A.
    Cunningham, David
    Chadwick, Nick
    Counsell, Nicholas
    Lawrie, Anthony
    Jack, Andrew
    Smith, Paul
    Mouncey, Paul
    Pocock, Christopher
    Ardeshna, Kirit M.
    Radford, John
    McMillan, Andrew
    Davies, John
    Turner, Deborah
    Kruger, Anton
    Johnson, Peter W. M.
    Gambell, Joanna
    Linch, David
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 175 (04) : 668 - 672
  • [33] PHASE 1B STUDY COMBINING IBRUTINIB WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (R-CHOP) IN PATIENTS WITH CD20-POSITIVE B-CELL NON-HODGKIN LYMPHOMA (NHL)
    Younes, A.
    Flinn, I.
    Berdeja, J.
    Friedberg, J.
    Alberti, S.
    Thieblemont, C.
    Morschhauser, F.
    Hellemans, P.
    Hall, B.
    Smit, J.
    Skee, D.
    de Vries, R.
    Todorovic, M.
    Khan, I.
    Fourneau, N.
    Oki, Y.
    HAEMATOLOGICA, 2013, 98 : 356 - 356
  • [34] Safety and Efficacy of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of the Phase II Avr-CHOP Study
    Hawkes, Eliza A.
    Chong, Geoffrey
    Smith, Charmaine
    Lee, Sze-Ting
    Churilov, Leonid
    McKendrick, Joseph
    Renwick, William
    Blombery, Piers
    Nelson, Niles Elizabeth
    Fancourt, Tineke
    Hawking, Joanne
    Lin, Wendi
    Scott, Andrew M.
    Barraclough, Allison
    Wight, Joel
    Grigg, Andrew
    Keane, Colm
    Fong, Chun Yew
    Manos, Kate
    BLOOD, 2020, 136
  • [35] Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
    Mounier, N
    Briere, J
    Gisselbrecht, C
    Emile, JF
    Lederlin, P
    Sebban, C
    Berger, F
    Bosly, A
    Morel, P
    Tilly, H
    Bouabdallah, R
    Reyes, F
    Gaulard, P
    Coiffier, B
    BLOOD, 2003, 101 (11) : 4279 - 4284
  • [36] CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab) compared to CPOP-R (cyclophosphamide, pixantrone, vincristine, prednisone, rituxamib) in first-line therapy of diffuse large B cell lymphoma (DLBCL): An interim analysis
    Herbrecht, Raoul
    Couban, Stephen
    Weissinger, Florian
    Gorbatchevsky, Igor
    van der Jagt, Richard H.
    BLOOD, 2007, 110 (11) : 1009A - 1010A
  • [37] Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study
    Davies, Andrew J.
    Caddy, Josh
    McLaughlin, Katy
    Wignall, Christopher
    Waugh, Robert
    Collins, Graham P.
    Stanton, Louise
    Saunders, Geoff N.
    Cummin, Thomas
    Schuh, Anna
    Ardeshna, Kirit M.
    McMillan, Andrew K.
    Radford, John
    Lewis, David John
    Coleman, Adam R.
    Griffiths, Gareth
    Burton, Cathy
    Barrans, Sharon
    Johnson, Peter
    BLOOD, 2022, 140 : 9478 - 9479
  • [38] Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial
    Yuqin Song
    Hui Zhou
    Huilai Zhang
    Wei Liu
    Yuerong Shuang
    Keshu Zhou
    Fangfang Lv
    Hao Xu
    Jianfeng Zhou
    Wei Li
    Huaqing Wang
    Hongyu Zhang
    Haiwen Huang
    Qingyuan Zhang
    Wei Xu
    Zheng Ge
    Ying Xiang
    Shuye Wang
    Da Gao
    Shun’e Yang
    Jinying Lin
    Lin Wang
    Liqun Zou
    Meifang Zheng
    Jing Liu
    Zonghong Shao
    Ying Pang
    Ruixiang Xia
    Zhendong Chen
    Ming Hou
    Hongxia Yao
    Ru Feng
    Zhen Cai
    Mingzhi Zhang
    Wenhua Ran
    Lin Liu
    Shan Zeng
    Wei Yang
    Peng Liu
    Aibin Liang
    Xuelan Zuo
    Qingfeng Zou
    Junxun Ma
    Wei Sang
    Ye Guo
    Wei Zhang
    Yongqing Cao
    Yan Li
    Jifeng Feng
    Xin Du
    Advances in Therapy, 2021, 38 : 1889 - 1903
  • [39] Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial
    Song, Yuqin
    Zhou, Hui
    Zhang, Huilai
    Liu, Wei
    Shuang, Yuerong
    Zhou, Keshu
    Lv, Fangfang
    Xu, Hao
    Zhou, Jianfeng
    Li, Wei
    Wang, Huaqing
    Zhang, Hongyu
    Huang, Haiwen
    Zhang, Qingyuan
    Xu, Wei
    Ge, Zheng
    Xiang, Ying
    Wang, Shuye
    Gao, Da
    Yang, Shun'e
    Lin, Jinying
    Wang, Lin
    Zou, Liqun
    Zheng, Meifang
    Liu, Jing
    Shao, Zonghong
    Pang, Ying
    Xia, Ruixiang
    Chen, Zhendong
    Hou, Ming
    Yao, Hongxia
    Feng, Ru
    Cai, Zhen
    Zhang, Mingzhi
    Ran, Wenhua
    Liu, Lin
    Zeng, Shan
    Yang, Wei
    Liu, Peng
    Liang, Aibin
    Zuo, Xuelan
    Zou, Qingfeng
    Ma, Junxun
    Sang, Wei
    Guo, Ye
    Zhang, Wei
    Cao, Yongqing
    Li, Yan
    Feng, Jifeng
    Du, Xin
    ADVANCES IN THERAPY, 2021, 38 (04) : 1889 - 1903
  • [40] Rituximab plus CHOP (R-CHOP) in the treatment of elderly patients with diffuse large B-cell lymphoma.: An update of the GELA study.
    Coiffier, B
    Fermé, C
    Hermine, O
    Haioun, C
    Baumelou, E
    Solal-Celigny, P
    Delmer, A
    Sebban, C
    Mounier, N
    Tertian, G
    Van Hoof, A
    Bosly, A
    BLOOD, 2001, 98 (11) : 725A - 725A
12345